Centivax
Accelerating the world's transition to a post-pathogen humanity.
- Headquarters
- San Francisco, California
- Employees
- 11–50
- Founded
- 2019
- Business Model
- B2B
- Website
- centivax.com
- Total Funding
- $55.0M
- Last Round
- $45.0M Series AJul 2025
About
Centivax is a clinical-stage universal immunity company deploying a proprietary computational immune-engineering platform to develop broad-spectrum vaccines and therapeutic antibodies. Founded in 2019 by computational immunologist Jacob Glanville, the company's lead program is a universal influenza vaccine currently in Phase 1 clinical trials, which was awarded a Gates Foundation Grand Challenge. Centivax is also developing universal vaccines for other pathogens and antivenom therapies. The company is headquartered in South San Francisco, California and has raised over $55 million in funding.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account